Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,100
Employees6,100
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,100
Employees6,100

VRTX Key Statistics

Market cap
112.87B
Market cap112.87B
Price-Earnings ratio
-112.01
Price-Earnings ratio-112.01
Dividend yield
Dividend yield
Average volume
2.62M
Average volume2.62M
High today
$441.10
High today$441.10
Low today
$412.72
Low today$412.72
Open price
$425.00
Open price$425.00
Volume
1.98M
Volume1.98M
52 Week high
$519.88
52 Week high$519.88
52 Week low
$377.85
52 Week low$377.85

VRTX News

TipRanks 3d
Skechers, Shopify, Diamondback, Vertex, Turtle Beach: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (SKX) ), ( (SHOP) ), ( (FANG) ), ( (VRTX) ) and ( (TBCH) ). Here is a breakdown of their recent ratings and the rati...

TipRanks 6d
Vertex Pharmaceuticals price target raised to $499 from $467 at Barclays

Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $499 from $467 and keeps an Equal Weight rating on the shares. The company announced...

TipRanks 6d
Wolfe downgrades Vertex Pharmaceuticals on slow pain launch

Wolfe Research analyst Andy Chen last night downgraded Vertex Pharmaceuticals (VRTX) to Peer Perform from Outperform without a price target The company’s Q1 ear...

Analyst ratings

51%

of 35 ratings
Buy
51.4%
Hold
42.9%
Sell
5.7%

More VRTX News

Benzinga 7d
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings p...

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Simply Wall St 7d
Vertex Pharmaceuticals (NasdaqGS:VRTX) Raises Guidance Despite Intangible Asset Impairment Charge

recently reported a decline in net income and EPS for Q1 2025, despite a rise in revenue, which was accompanied by a large $379 million impairment charge relate...

Vertex Pharmaceuticals (NasdaqGS:VRTX) Raises Guidance Despite Intangible Asset Impairment Charge
Benzinga 7d
This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.